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Conclusions: In this randomized Phase II trial of 1st-line advanced 
NSCLC, vandetanib + CP met the primary endpoint of prolonging PFS 
vs CP but did not provide a detectable survival advantage. Treatment 
options with vandetanib in 1st-line NSCLC continue to be explored, 
and Phase III evaluation of vandetanib in advanced, previously treated 
NSCLC is ongoing. 
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Background: We hypothesised that thalidomide, an oral anti-angio-
genic agent with tumour vasculature stabilising, anti-cachexic and im-
muno-modulatory properties, when combined with chemotherapy and 
as maintenance treatment would improve survival in patients with stage 
IIIb or IV NSCLC. Thalidomide has already been shown to be effective 
in treating myeloma. Here, we present the preliminary ﬁndings of the 
largest phase III trial of thalidomide conducted in NSCLC to date. 
Methods: Chemo-naive patients with pathologically proven NSCLC, 
Stage IIIb or IV disease and ECOG performance status (PS) 0-2 were 
entered into a double-blind placebo-controlled trial from 66 centres 
in the UK. Patients had adequate renal and haematologic function for 
platinum based treatment and an estimated life expectancy of greater 
than 8 weeks. All patients received up to 4 cycles of Gemcitabine 1200 
mg/m2 IV (days 1 & 8 of 21 day cycle) and Carboplatin AUC 5 (day 1). 
Patients were randomised to receive placebo or thalidomide taken oral-
ly from the start of chemotherapy and then daily for up to 2 years. The 
thalidomide/placebo dose began at 100mg/day during chemotherapy. If 
the patient was able to tolerate this dose, it was increased to 150mg/day 
after the last chemotherapy cycle for one month, then to 200mg/day for 
the rest of the trial. Strict guidelines were given regarding pregnancy 
testing and contraceptive measures. The study end-points were overall 
survival, time to disease progression, response rates, toxicity and qual-
ity of life. The trial had 80% power to show a difference in the overall 
survival rate at 2 years of 7% (from 12 to 19%).
Results: Between 2003 and 2006, 722 patients were randomized (pla-
cebo n=350; thalidomide n =372). The median age was 63 yrs (range 
33-84 ); 64% were male; main histological subtypes were adenocarci-
noma (36%) and squamous cell carcinoma (32%); 44% had stage IIIB 
and 56% had stage IV disease; and majority had good performance 
status (ECOG score of 0 and 1 were 31%, 59% respectively). Base-
line patient characteristics were well balanced between the arms. The 
proportions of patients completing all 4 intended chemotherapy cycles 
were 67% (placebo) and 65% (thalidomide), and the proportions of 
patients who had their chemotherapy dose delayed or reduced were 
similar between the trial arms. At the time of this analysis the median 
follow-up in all patients was 18 months and 620 had died (295 placebo 
and 325 thalidomide), of which 90% were reported to have died from 
lung cancer. There was no evidence of a difference in overall sur-
vival. The median survival was 8.9 months (placebo) and 8.4 months 
(thalidomide). The hazard ratio was 1.13 (95% CI 0.96 to 1.32), p=0.14 
from a logrank test. The 2-year survival rate was 14% and 10% in the 
placebo and thalidomide arms respectively. Subgroup analyses based 
on gender, age, performance status, tumour stage and cell type did not 
provide any evidence of a beneﬁcial effect of thalidomide for any of 
these factors. The results on progression-free survival were consistent 
with those on overall survival, and again showed no survival effect of 
using thalidomide. The main adverse effect associated with thalidomide 
was a thrombotic event and this was easily treated with anti-coagulants. 
117 patients experienced at least one such event (mainly pulmonary 
embolus and deep vein thrombosis) with 20% in the thalidomide arm 
compared to 12% on placebo - relative risk of 1.68 (95% CI 1.19 to 
2.38). There was no statistically signiﬁcant difference in haematologi-
cal toxicities, 40% (placebo) vs 43% (thalidomide), or non-haemato-
logical toxicities (excluding thrombotic events), 16% (placebo) vs 19% 
(thalidomide). 
Conclusions - Preliminary analyses demonstrated that thalidomide 
in combination with gemcitabine and carboplatin and as maintenance 
treatment in chemotherapy-naive NSCLC patients did not improve sur-
vival and progression-free survival over gemcitabine and carboplatin 
alone and was associated with increased thrombotic events. The ﬁnal 
analyses, including those on quality of life and response rates, will be 
presented for both treatment groups.
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Background: RAD001®, an oral inhibitor of the mammalian target of 
rapamycin (mTOR) that has shown anti-tumor activity both as single-
agent and in combination with other anticancer agents in in vitro and 
in vivo NSCLC models. In a phase I study, 4 disease stabilizations 
(SD) and 1 partial response (PR) as per RECIST were reported from 14 
NSCLC pts treated with R monotherapy.
Methods: Advanced NSCLC pts with adequate organ function, perfor-
mance status ≤ 2, failing either ≤ 2 C (arm 1) or ≤ 2 C and an EGFR-I 
(arm 2) were treated with R at 10 mg qd if tolerable until progression 
(PD). The study applied a Simon-2-stage design with primary endpoint 
of objective tumor response rate (RR) according to RECIST. CT scans 
were performed every 28 days until month 4 and then every 2 months 
thereafter. Adverse events (AE) were assessed using NCI CTC v.3.0. 
Biomarker analysis was performed on tumor tissues.
Results: This analysis is based on data acquired up to 20Sep2006. 85 
pts were enrolled between Aug 2005 and May 2006. Demographics and 
patient disposition were (arm 1/arm 2): 42/43 (7 pts ongoing), female 
38.1%/51.2%, never smoker 14.3%/44.2%, adenoca. 57.1%/62.8%, 
